



09-240

RCE/16448
#12

Express Mail Mailing Label No.750476423US

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

ADDRESS TO: Box RCE
Assistant Commissioner for Patents
Washington, D.C. 20231

Application No.	09/292,217
Filing Date	April 15, 1999
First Named Inventor	Gillies
Group Art Unit	1644
Examiner Name	Roark J.
Attorney Docket No.	LEX-004

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTES

RCE v. CPA: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA.

FEES AND SUBMISSION REQUIRED: A submission as used in this section includes, but is not limited to, an information disclosure statement; an amendment to the written description, claims, or drawings; new arguments, or new evidence in support of patentability. If reply to an Office action under 35 U.S.C. 132 is outstanding, the submission must meet the reply requirements of § 1.111 (see 37 C.F.R. 1.114 (c)).

RCE APPLIES TO: An application in which prosecution is closed (see 37 C.F.R. § 1.114 (b)).

RCE DOES NOT APPLY TO: (1) A provisional application; (2) an application for a utility or plant patent filed under 35 U.S.C. 111(a) before June 8, 1995; (3) an international application filed under 35 U.S.C. 363 before June 8, 1995; (4) an application for a design patent; or (5) a patent under reexamination (see 37 C.F.R. 1.114(e)).

1. SUBMISSION REQUIRED UNDER 37 C.F.R. § 1.114

- a. Enter and consider the unentered amendment under 37 C.F.R. § 1.116 previously filed on ____.
- b. Consider the arguments in the Appeal Brief or Reply Brief previously filed on ____.
- c. Amendment/Response enclosed. (8 pages)
- d. Affidavit(s)/Declaration(s) enclosed.
- e. Supplemental Information Disclosure Statement (IDS) enclosed. (2 pages)
 - i. PTO-1449
 - ii. Copy of IDS Citation (CAG)
- f. Other _____


2. RCE FEE REQUIRED UNDER 37 C.F.R. § 1.114

- a. Small entity status
 - i. was established in the prior nonprovisional application.
 - ii. is established herewith by the enclosed written assertion of entitlement to small entity status.
- b. A Petition and Fee for Extension of Time for 3 months up to and including September 20, 2001, is enclosed herewith.
- c. A check in the amount of \$ 710.00 and a check in the amount of \$890.00 is enclosed.
- d. The Commissioner is hereby authorized to charge the required fee(s), i.e., \$____, to Deposit Account No. 20-0531.
- e. The Commissioner is hereby authorized to credit overpayments or charge any additional fees required for this submission under 37 C.F.R. §§ 1.16 and 1.17 to Deposit Account No. 20-0531.

TECH CENTER 1600/2900
RECEIVED
SEP 27 2001

3. MISCELLANEOUS

- a. Return Receipt Postcard enclosed.
b. Other _____.

CORRESPONDENCE ADDRESS	SIGNATURE BLOCK
Direct all correspondence to: Patent Administrator Testa, Hurwitz & Thibeault, LLP High Street Tower 125 High Street Boston, MA 02110 Tel. No.: (617) 248-7000 Fax No.: (617) 248-7100	Date: September 20, 2001 Reg. No.: 1014 41418 Tel. No.: (617) 248-7240 Fax No.: (617) 248-7100 Respectfully submitted,  Patrick R.H. Wall Agent for the Applicant Testa, Hurwitz & Thibeault, LLP High Street Tower 125 High Street Boston, MA 02110

2179267

PATENT
Atty. Docket No. LEX-004
(4006/15)

#13/B
gnd
10/9/01



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Gillies

SERIAL NUMBER: 09/292,217 GROUP NUMBER: 1644

FILING DATE: April 15, 1999 EXAMINER: J.H. Roark

TITLE: ENHANCEMENT OF ANTIBODY-CYTOKINE FUSION
PROTEIN MEDiated IMMUNE RESPONSE BY CO-
ADMINISTRATION WITH ANGIOGENESIS INHIBITOR

Box RCE
Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
TECH CENTER 1600/2900
SEP 21 2001

AMENDMENT AND RESPONSE

Sir:

In response to the Final Office action mailed on March 20, 2001, in connection with the above-identified patent application, Applicant submits this Amendment and Response along with a Request for Continued Examination. A petition and appropriate fee for a three month extension of time up to and including September 20, 2001, is submitted herewith.

Reconsideration and withdrawal of the rejections are requested in light of the following amendments and remarks.

AMENDMENTTo the Claims

Please amend claims 1, 2, 3, 8, 12, 17, 20, 23, 27, 31, and 36 to read as follows. A marked up version of the amended claims is attached at the end of this Amendment and Response.

Sub C
B1
1.(Amended) A method of inducing a cytoidal immune response against a target cell, in a mammal, the method comprising:

administering to a mammal a combination of (i) an immunoconjugate comprising an antibody binding site capable of binding a target antigen expressed on a target cell and a cytokine, and (ii) an angiogenesis inhibitor,

wherein the combination induces a cytoidal immune response against the target cell that is greater than a response induced by the immunoconjugate alone.